Suchergebnisse - "Kates, Ronald"

PubPharm (120)

1

Favorable impact of therapy management by an interactive eHealth system on severe adverse events in patients with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer treated by palbociclib and endocrine therapy

enthalten in: Cancer treatment reviews | 2023

von Harbeck, N. | Kates, R. | Schinköthe, T. | +15

2

Development and validation of multivariate predictors of primary endocrine resistance to tamoxifen and aromatase inhibitors in luminal breast cancer reveal drug-specific differences

enthalten in: bioRxiv.org | 2023

von Zhang, G. | Jurinovic, V. | Bartels, S. | +19

3

PRECYCLE: Multicenter, Randomized Phase IV Intergroup Trial to Evaluate the Impact of E Health-Based Patient Reported Outcome (PRO) Assessment on Quality of Life in Patients with Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Treated with Palbociclib and an Aromatase Inhibitor- or Palbociclib and Fulvestrant

enthalten in: ResearchSquare.com | 2023

von Degenhardt, T. | Fasching, P. | Lüftner, D. | +19

4

De-Escalated Neoadjuvant Trastuzumab-Emtansine With or Without Endocrine Therapy Versus Trastuzumab With Endocrine Therapy in HR+/HER2+ Early Breast Cancer : 5-Year Survival in the WSG-ADAPT-TP Trial

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2023

von Harbeck, N. | Nitz, U. | Christgen, M. | +25

5

Efficacy of Endocrine Therapy Plus Trastuzumab and Pertuzumab vs De-escalated Chemotherapy in Patients with Hormone Receptor-Positive/ERBB2-Positive Early Breast Cancer : The Neoadjuvant WSG-TP-II Randomized Clinical Trial

enthalten in: JAMA oncology | 2023

von Gluz, O. | Nitz, U. | Christgen, M. | +17

6

PRECYCLE : multicenter, randomized phase IV intergroup trial to evaluate the impact of eHealth-based patient-reported outcome (PRO) assessment on quality of life in patients with hormone receptor positive, HER2 negative locally advanced or metastatic breast cancer treated with palbociclib and an aromatase inhibitor or palbociclib and fulvestrant

enthalten in: Trials | 2023

von Degenhardt, T. | Fasching, P. | Lüftner, D. | +20

7

PRECYCLE: multicenter, randomized phase IV intergroup trial to evaluate the impact of eHealth-based patient-reported outcome (PRO) assessment on quality of life in patients with hormone receptor positive, HER2 negative locally advanced or metastatic breast cancer treated with palbociclib and an aromatase inhibitor or palbociclib and fulvestrant

enthalten in: Trials | 2023

von Degenhardt, T. | Fasching, P. | Lüftner, D. | +19

8

Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2+/HR- Trial

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2023

von Graeser, M. | Gluz, O. | Biehl, C. | +24

9

De-escalated Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC) : Impact of Molecular Markers and Final Survival Analysis of the WSG-ADAPT-TN Trial

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2022

von Gluz, O. | Nitz, U. | Kolberg-Liedtke, C. | +23

CommentOn: Clin Cancer Res. 2022 Nov 14;28(22):4840-4842. - PMID 36083131

10

Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trial

enthalten in: Breast cancer research : BCR | 2022

von Kolberg-Liedtke, C. | Feuerhake, F. | Garke, M. | +17

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[12]